Trial Profile
An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Rogaratinib (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- Acronyms FORT-2
- Sponsors Bayer
- 04 Aug 2023 Planned End Date changed from 22 Dec 2023 to 30 Aug 2024.
- 28 Apr 2023 According to ClinicalTrials.gov record, protocol has been amended to change the primary endpoints and trial focus from TU and AR to AR.
- 23 Feb 2023 This trial has been completed in Austria, according to European Clinical Trials Database record.